

Comparison of Recommendations for Screening Mammography Using CISNET Models

Elizabeth Kagan Arleo, MD¹; R. Edward Hendrick, PhD²; Mark A. Helvie, MD³; and Edward A. Sickles, MD⁴

BACKGROUND: Currently, there are several different recommendations for screening mammography from major national health care organizations, including: 1) annual screening at ages 40 to 84 years; 2) screening annually at ages 45 to 54 years, then biennially at ages 55 to 79 years; and 3) biennial screening at ages 50 to 74 years. **METHODS:** Mean values of six Cancer Intervention and Surveillance Modeling Network (CISNET) models were used to compare these three screening mammography recommendations in terms of benefits and risks. **RESULTS:** Mean mortality reduction was greatest with the recommendation of annual screening at ages 40 to 84 years (39.6%), compared with the hybrid recommendation of screening annually at ages 45 to 54 years, then biennially at ages 55 to 79 years (30.8%), and the recommendation of biennial screening at ages 50 to 74 years (23.2%). For a single-year cohort of US women aged 40 years, assuming 100% compliance, more breast cancers deaths would be averted over their lifetime with annual screening starting at age 40 (29,369) than with the hybrid recommendation (22,829) or biennial screening ages 50-74 (17,153 based on 2009 CISNET estimates, 15,599 based on 2016 CISNET estimates). To achieve the greatest mortality benefit, this single-year cohort of women would have the greatest total number of screening mammograms, benign recalls, and benign biopsies performed over the course of screening by following annual screening starting at age 40 years (90.2 million, 6.8 million, and 481,269, respectively) than by following the hybrid recommendation (49.0 million, 4.1 million, and 286,288, respectively) or biennial screening at ages 50 to 74 years (27.3 million, 2.3 million, and 162,885, respectively). **CONCLUSION:** CISNET models demonstrate that the greatest mortality reduction is achieved with annual screening of women starting at age 40 years. *Cancer* 2017;123:3673-80. © 2017 American Cancer Society.

KEYWORDS: breast cancer, life-years gained, lives saved, mammography, mortality benefit, screening.

INTRODUCTION

Breast cancer deaths are prevented by routine screening mammography, as evidenced by randomized controlled trials (RCTs), mortality data from organized population-based screening programs, and international service screening experience.¹ According to a meta-analysis of RCT data, the relative risk of dying from breast cancer was 20% less in women invited to screening mammography compared with women who were not.² National data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute indicate that after the widespread introduction of screening mammography in the late 1980s, the breast cancer death rate in the United States subsequently decreased by 37%,³ although this decline in death rate cannot entirely be attributed to screening. Among women who actually underwent screening mammography, incidence-based mortality studies based on service screening data from Europe and Canada have demonstrated a 38% to 40% decrease in breast cancer deaths,^{4,5} and case-control studies based on service screening data from Europe and Australia have demonstrated a 48% to 49% decrease in breast cancer deaths.^{4,6}

These RCTs, US population-based data, and international service screening data are not without their limitations, however, including the use of older mammography technology and the issues of noncompliance and contamination, both of which underestimate the benefit of current practice on women undergoing screening (RCTs), lack of information about which women were actually screened (SEER population-based data), and differences in screening intervals and starting ages (service screening).^{2,4,7-9} Computer models, although also not without limitations, attempt to rectify some of the shortcomings of the data previously mentioned by applying consistent starting ages and screening intervals both within and across various models. Under the auspices of the National Institutes of Health, which is part of the US Department of Health and Human Services, the National Cancer Institute has funded the Cancer Intervention and Surveillance Modeling Network (CISNET) to develop such models.¹⁰⁻¹² In 2009 and 2016, the US Preventive Services Task Force (USPSTF) issued recommendations on screening for breast cancer, informed by reports from CISNET.^{13,14}

Corresponding author: R. Edward Hendrick, PhD, Anschutz Medical Campus, 12700 E. 19th Ave., Mail Stop C278, Aurora, CO 80045; edward.hendrick@gmail.com

¹Weill Cornell Imaging at New York-Presbyterian, New York, New York; ²Department of Radiology, University of Colorado-Denver, School of Medicine, Denver, Colorado; ³Department of Radiology and Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI; ⁴Department of Radiology, University of California, San Francisco, California

See referenced editorial on pages 3656-9, this issue.

DOI: 10.1002/cncr.30842, **Received:** August 16, 2016; **Revised:** January 12, 2017; **Accepted:** February 5, 2017, **Published online** August 21, 2017 in Wiley Online Library (wileyonlinelibrary.com)

TABLE 1. Mammography Screening Recommendations of Various National Organizations

Recommending Organizations	Screening Frequency	Starting Age	Stopping Age
ACOG, ACR, ^a NCBC, NCCN, SBI ^a	Annual	40 y	Life expectancy <5-7 y ^a
ACS, ASBS, ASCO	Annual to age 54 y; biennial age ≥55 y, with option for annual	45 y, with option to start at 40 y	Life expectancy <10 y
AAFP, ACP, USPSTF	Biennial	50 y	74 y

Abbreviations: AAFP, American Academy of Family Physicians; ACOG, American College of Obstetricians and Gynecologists; ACP, American College of Physicians; ACR, American College of Radiology; ACS, American Cancer Society; ASBS, American Society of Breast Surgeons; ASCO, American Society of Surgical Oncology; NCBC, National Consortium of Breast Centers; NCCN, National Comprehensive Cancer Center Network; SBI, Society of Breast Imaging; USPSTF, US Preventive Services Task Force.

^aThe ACR and SBI recommend stopping screening when life expectancy is less than 5-7 years; the other three organizations recommending annual screening starting at age 40 do not specify a screening stopping point

The purpose of this study was to use CISNET breast cancer models to compare the three most widely discussed current screening mammography recommendations for women of average breast cancer risk: 1) annual screening at ages 40 to 84 years (hereafter referred to as annual screening starting at age 40 years); 2) annual screening at ages 45 to 54 years, followed by biennial screening at ages 55 to 79 years; and 3) biennial screening at ages 50 to 74 years. Although CISNET itself has compared screening strategies,¹² it is precisely because the most recent CISNET analysis involved only one of the three most widely discussed strategies that the current study was performed.

SUBJECTS AND METHODS

We used the 2009 and 2015-2016 CISNET breast cancer-specific models (hereafter referred to as 2009 CISNET and 2016 CISNET, respectively) to analyze the implications of different screening recommendations, including: 1) annual screening starting at age 40 years; 2) annual screening at ages 45 to 54 years, followed by biennial screening at ages 55 to 79 years; and 3) and biennial screening at ages 50 to 74 years. Table 1 outlines the screening recommendations of various organizations. The methods CISNET used to develop their models are detailed in a technical report published by the Agency for Healthcare Quality and Research.¹¹ In brief, CISNET had six groups at different institutions develop independent computer models with multiple input parameters including estimates of breast cancer incidence, survival trends with and without screening or adjuvant therapy, mammography performance data from the Breast Cancer Surveillance Consortium (BCSC), and breast cancer-specific mortality data from the SEER Program. However, the models are each different, and although estimates of outcomes are somewhat similar, there are significant differences among the six models, as well as inherent imprecision in models in general. For more details, the specific model parameters and inputs can be found on the

CISNET website.¹⁵ All CISNET models assume 100% adherence to screening and treatment. A factor that cannot be controlled is the quality of diagnostic studies and treatment; although high quality is assumed given mammography requirements under the Mammography Quality Standards Act and surgical and oncological standards, realistic variations might be expected.

CISNET quantified benefits in terms of breast cancer deaths averted and life-years gained by screening per 1000 women based on a single-year cohort of US women: those born in 1960 for 2009 CISNET and those born in 1970 for 2016 CISNET. Benefits in terms of lives saved, life-years gained, and estimates of number needed to screen to avert a breast cancer death assume follow-up over each woman's lifetime. We have extended 2009 CISNET to obtain absolute numbers of women who would both benefit and experience risk from screening over the full age range specified for the single birth-year cohort of U.S. women born in 1960 and alive in the year 2000 (2.468 million based on year 2000 US census data¹⁶). A woman born in 1960 and alive in 2000 would be 40 years old and enter the age range that screening begins for the first of the three screening strategies. In our comparison of screening strategies, some women begin screening at age 40 years, some at age 45 years, and some at age 50 years, and all attend annually or biennially, or a combination of the two, until screening ends. Benefits are also stated in terms of numbers needed to screen (NNS) to avert one breast cancer death and to gain 1 life-year for each strategy. Use and risks of screening are quantified in terms of numbers of mammograms, benign recalls (women recalled from screening with no significant or nonmalignant findings), and benign biopsies performed, both per 1000 women screened and in absolute numbers for that single birth-year cohort. Because both CISNET modelers and the USPSTF acknowledge that "methods for estimating overdiagnosis at a population level are not well established"^{12,14,17} and "Existing science does not allow for the ability to determine precisely what proportion of cancer diagnosed by

TABLE 2. Comparison of Mammography Use and Benefits of the 3 Major Screening Mammography Strategies Based on Mean Values of the 6 2009 CISNET Models

Screening Strategy ^a	No. of Examinations ^b	Percent Mortality Reduction	Breast Cancer Deaths Averted ^b	LYG ^b	NNS per Death Averted	NNS per LYG
A40-84	36,550	39.6%	11.9	189	84	5.3
H45-79	19,846	30.8%	9.25	149	108	6.7
B50-74	11,066	23.2%	6.95	110	144	9.1

Abbreviations: LYG, life-years gained; NNS, numbers needed to screen.

^aA40-84: annual screening mammography at age 40 to 84 years. H45-79: hybrid strategy consisting of annual screening at age 45 to 54 years, then biennial screening at age 55 to 79 years. B50-74: biennial screening age 50 to 74 years.

^bPer 1000 women screened.

mammography today reflects overdiagnosis, and estimates vary widely depending on the data source and method of calculation used,¹¹ the decision was made not to include overdiagnosis in this study's risk assessment. However, unless breast cancers actually can regress and disappear (which no one has ever observed for an invasive cancer found by mammography), delaying the age at which screening is started and extending the time between screens will have no effect on "overdiagnosis", since "overdiagnosed" cancers still will be present at the age of 45 or 50 and still will be present whether screening is annual or biennial.

CISNET estimates in 2009 considered annual and biennial screening for a variety of starting and ending ages (extending to age 84 years). For both annual and biennial screening, by taking differences between 2009 CISNET estimates over wider age ranges, we estimate benefits and risks over a variety of age ranges, including those of the three major models, including the hybrid recommendation of screening annually at ages 45 to 54 years, then biennially at ages 55 to 79 years.

CISNET estimates in 2009 used 6 models to estimate benefit, whereas only 1 model, their "exemplar" Stanford model, was used to provide quantitative estimates of risks. We report the mean benefits across all 6 models, weighing each model equally. The first and second recommendations, 1) annual screening starting at age 40 years and 2) annual screening at ages 45 to 54 years followed by biennial screening at ages 55 to 79 years, recommend that a healthy woman continue screening until her life expectancy is less than 10 years (second recommendation) or less than 5-7 years (first recommendation). Based on 2010 life expectancy tables,¹⁸ the average US woman's life expectancy drops below 10 years at age 80 to 81 years and below 7 years at age 85 to 86 years. Based on these life expectancies, we estimate benefits and risks using 2009 CISNET taking age 79 as the final screening age for the average woman following the second recommendation, and age 84 as the final screening age for the average woman following the first recommendation.

2016 CISNET included 6 models to provide quantitative estimates of benefits and risks. Estimates of benefits and risks in 2016 CISNET were based on the single birth-year cohort of US women born in 1970 and alive in the year 2010 (2.197 million based on 2010 US census data¹⁶). Compared with 2009 CISNET estimates, 2016 CISNET estimates involved a smaller number of annual, biennial, and hybrid screening scenarios, with all scenarios ending screening at age 74 years. Specifically, 2016 CISNET assessed only one of the three currently considered screening recommendations (the third), because all screening scenarios considered by 2016 CISNET ended screening at age 74 years, and because the only hybrid strategies 2016 CISNET considered transitioned from annual to biennial screening at age 50 years, rather than the second hybrid recommendation of transitioning from annual to biennial screening at age 55 years. Because neither the second hybrid nor the first recommendation is modeled by 2016 CISNET, we use 2009 CISNET models to compare the three current recommendations for screening mammography. We also compare CISNET 2009 and 2016 estimates of benefits and risks for the third screening recommendation of biennial screening of women ages 50 to 74 years. 2009 CISNET was based largely on screen-film mammography performance, while 2016 CISNET was based primarily on digital mammography performance. As of June 1, 2016, 98% of the 16,042 mammography units in the United States were digital mammography units.¹⁹

Statistical analyses were not performed because assessing for statistical significance of differences was not the objective of this study; rather, the goal was to quantify the benefits and risks estimated by CISNET models and our extension of CISNET models for the 3 major screening recommendations.

RESULTS

Table 2 shows the benefits of screening mammography over a lifetime of compliance with each of the three major

TABLE 3. Data for Single-Year Cohort of Women Born in 1960 and Alive in 2000 (2.468 million) Who Followed Each Screening Regimen, Based on 2009 CISNET Models

Screening Strategy ^a	Total No. of Mammographic Examinations	Total Deaths Averted	Total LYG	Total No. of Negative Recalls	Total No. of Benign Biopsies	LYG per Benign Biopsy
A40-84	90.2 million	29,369	466,452	6.8 million	481,260	1.0
H45-79	49.0 million	22,829	367,732	4.1 million	286,288	1.3
B50-74	27.3 million	17,153	271,480	2.3 million	162,888	1.7

^aA40-84: annual screening mammography at age 40 to 84 years. H45-79: hybrid strategy consisting of annual screening at age 45 to 54 years, then biennial screening at age 55 to 79 years. B50-74: biennial screening age 50 to 74 years.

screening recommendations based on 2009 CISNET modeling.¹⁰ Table 2 demonstrates that the largest mean mortality reduction is achieved with the first recommendation of annual screening starting at age 40 years (39.6% vs 30.8% for the second recommendation and 23.2% for the third). Similarly, following the first recommendation averts the most breast cancer deaths (11.9 per 1000 women screened, 29% more than the hybrid recommendation and 71% more than the third recommendation) and gains the most life-years (189 per 1000 women screened vs 149 for the hybrid recommendation and 110 for the third recommendation).

Table 2 also demonstrates that the NNS per death averted and the NNS per life-year gained (LYG) was smallest—and therefore most efficacious—with the first recommendation (NNS per death averted of 84 for the first vs 108 for the hybrid and 144 for the third recommendation; NNS per LYG of 5.3 for the first, 6.7 for the hybrid, 9.1 for the third recommendation, respectively).

Table 3 shows the benefits of screening mammography for the single-year cohort of women who turned 40 years old in 2000 and who followed each recommendation. If none of these women underwent screening mammography, the 2009 CISNET estimates that from age years 40, 3%,¹⁰ or approximately 74,000 women in this single-year cohort of 2,468,000 women would die due to breast cancer. Alternatively, if this cohort of women followed the first recommendation of annual screening at ages 40 to 84 years with 100% compliance, then 29,369 breast cancer deaths could be averted, a 39.6% mortality reduction. This is 29% more deaths averted than by the same group of women following the hybrid recommendation (22,829 deaths averted, a 30.8% mortality reduction) and 71% more deaths averted than by the same group following the third recommendation (17,153 deaths averted, a 23.2% mortality reduction). Likewise, the largest number of life-years would be gained if this single-year cohort followed the first recommendation (466,452 LYG), 27% more than if they followed the hybrid recommendation

(367,732 LYG), and 72% more than if they followed the third recommendation (271,480 LYG).

Table 3 also shows the risks of screening mammography in terms of recalls and benign biopsies for the single-year cohort of women who turned 40 years old in 2000 and who followed each recommendation. The largest number of screening mammograms, benign recalls, and benign biopsies would occur under the first recommendation, the smallest number under the third recommendation, and an intermediate number under the second (hybrid) recommendation. Based on these 2009 CISNET estimates, on average a woman getting annual screening starting at age 40 could expect to be recalled from screening for a benign diagnostic work-up once every 13 years, and could expect to undergo a benign biopsy once every 187 years. Benefit compared with risk is shown in the last column of Table 3 in terms of LYG per benign biopsy for each screening regimen. A woman getting annual screening starting at age 40 could expect 1 LYG for every benign biopsy.

Table 4 compares 2009 and 2016 CISNET estimates of benefit and risk for the third recommendation of biennial screening at ages 50 to 74 years. Although 2016 benefit estimates are slightly higher than 2009 estimates per 1000 women screened (9% higher for deaths averted, 10% higher for LYG) and benign recalls are 1% higher, benign biopsies are estimated to be 121% higher based on 2016 CISNET than those based on 2009 CISNET. One possible explanation is that 2009 estimates were based on BCSC data for the more clinically relevant outcome of biopsies actually performed, whereas 2016 estimates were based on BCSC data for radiologists' recommendations for biopsy¹⁰⁻¹²; in other words, more biopsies are recommended than are actually performed. Breast cancer deaths averted for a single-year cohort by biennial screening at ages 50 to 74 years are 17,153 based on 2009 CISNET, which used the cohort of women born in 1960, and 15,599 based on 2016 CISNET, which used the cohort of women born in 1970.^{10,12}

TABLE 4. Comparison of 2009 and 2016 CISNET Estimates of Benefits and Risks of the USPSTF-Recommended Strategy of Biennial Screening Between Age 50 and 74 Years

Biennial Screening at Age 50-74 Years ^a	No. of Examinations ^b	Median Mortality Reduction	Median Deaths Averted ^b	Median LYG ^b	Negative Recalls ^b	Benign Biopsies ^b
2009 CISNET	11,066	21.5%	6.5	111	940	66
2016 CISNET	11,127	25.8%	7.1	122	953	146

The median values for all 6 models are compared for benefit. Risks of negative recalls and benign biopsies are from the single “exemplar” Stanford model in 2009 and from all 6 models in 2016. The median rather than the mean values are reported for all parameters because 2016 CISNET did not report deaths averted per 1000 women screened for each of the 6 individual models.

^a2009 CISNET defined benign biopsies as the number of women undergoing benign biopsy, whereas 2016 CISNET changed their definition to the number of women recommended to undergo biopsy based on radiologic findings.

^bPer 1000 women screened.

The number of women in the single-year cohort of women born in 1960 who would still die from breast cancer given 100% compliance with screening, based on 2009 CISNET mean estimates, is 44,671 for the first strategy, 51,211 for the second strategy, and 56,887 for the third strategy.

DISCUSSION

The purpose of this study was to use CISNET breast cancer models to compare the three most widely discussed current recommendations for screening mammography: 1) annual screening starting at age 40 years; 2) screening annually at ages 45 to 54 years and biennially at ages 55 to 79 years; and 3) biennial screening at ages 50 to 74 years. The principal finding is that mean mortality reduction is greatest with the first recommendation of annual screening starting at age 40 years (39.6%) compared with the hybrid (30.8%) and third (23.2% based on 2009 CISNET, 26.6% based on 2016 CISNET) recommendations.

The primary value of analyzing 2016 CISNET results is to compare these new results with 2009 CISNET results to determine how CISNET estimates have changed. There are three main differences between 2009 and 2016 CISNET. First, 2016 CISNET modeled only one of the three major screening recommendations (biennial screening at ages 50 to 74 years). The second (hybrid) recommendation has women transitioning from annual to biennial screening at age 55 years rather than age 50 years, and in our comparison, on average ending screening at age 79 years rather than age 74 years; in our comparison, the first recommendation on average ends annual screening at age 84 years rather than age 74 years. Hence, 2016 CISNET does not model benefits or risks for either the first or second recommendation. It is important to point out that just because the 6 2016 CISNET models ended all screening strategies at age 74 years does not mean that women age 75 years and older do not continue to accrue benefits from screening mammography. In fact,

CISNET results demonstrate that, as CISNET itself reports, “for women with no comorbidity who have an average of a 17-year remaining life expectancy, screening would be efficient through age 78 to 80 years,”¹¹ and that benefits exceed risks up to age 90 years.²⁰

Second, CISNET changed its manner of calculating benign biopsies between 2009 and 2016. 2009 CISNET used BCSC data on the number of women actually undergoing benign biopsies, with positive predictive value (PPV) based on biopsies performed (PPV₃), whereas 2016 CISNET switched their definition to the number of women recommended to undergo biopsy based on radiology findings (PPV₂).²¹ It is important to understand that PPV₃ (CISNET 2009) is based on biopsies actually performed, which reflects actual health care delivery. As a result of this change in their definition of “negative biopsies,” 2016 CISNET may substantially overestimate the risk of benign biopsy. For example, using 2009 CISNET, biennial screening from ages 50 to 74 years was estimated to yield 66 benign biopsies per 1000 women screened, whereas 2016 CISNET estimated this number to be 146 (Table 4), 121% greater than the 2009 estimate. One can only speculate on why CISNET changed its method of estimating the number of benign biopsies. The number of women biopsied is the clinically relevant number, reflecting actual health care delivery, not the number of women recommended for biopsy.

A third difference between 2009 and 2016 CISNET involves the estimate of the number of women age ≥ 40 years who would die from breast cancer in the absence of screening mammography. The 2009 CISNET estimated median value for all 6 models was 3%, whereas the 2016 median value was 2.5% (range, 1.5%-3.2%)¹¹; CISNET’s rationale for this change is not fully explained. Effectively, CISNET substantially increased their estimate of the number of women who would benefit from treatment (adjuvant therapy and surgery) alone. This recalls the persistent conjecture in the literature that adjuvant therapy

has eclipsed the importance of early detection, despite the fact that numerous recent studies published demonstrate decreased breast cancer–specific deaths associated with invitation or exposure to screening mammography compared with women not invited or not attending screening.^{4,5,22-28} Evaluations of service screening programs have shown substantial mortality reductions in women exposed to screening compared with those not exposed to screening, with some studies going to great lengths to show that access to and quality of treatment was homogeneous across the comparison groups.²³ For example, Tabar et al²⁸ compared mortality reductions over time in exposed and unexposed women, showing that there was some improvement in deaths avoided due to modern therapy, but it was substantially less than deaths avoided by exposure to screening in combination with modern therapy; these estimates included interval cancers in the group exposed to screening who did not have their breast cancer diagnosed by screening. This study was unique in that it compared mortality reductions in unexposed women over the time period before and after the introduction of adjuvant therapy.²⁸ In these observational studies where women had access to the same therapies, there were fewer deaths among women who had access to screening, and even fewer among women who participated in screening, despite access to the same therapies. A recent CISNET analysis estimates that annual screening would account for the great majority (69%–74%) of breast cancer mortality reduction in the United States at full compliance.²⁹

Estimates of the number of women in the single-year cohort who would still die from breast cancer given 100% implementation of each of the 3 screening guidelines (44,671 with the first screening strategy, 51,211 with the second strategy, and 56,887 with the third strategy) highlight the need to improve breast screening, whether with mammography or another modality.

It is also of value to consider 2009 CISNET risk data from the individual woman's perspective and to highlight how frequently she is likely to experience "risks." Specifically, data in Table 3 show that if a woman born in 1960 and alive in the year 2000 underwent annual screening starting at age 40, then on average she could expect to be recalled for a benign diagnostic workup once every 13.3 screening examinations or approximately once every 13 years. Following that same screening recommendation, she could expect on average to undergo a benign biopsy once every 187 screening examinations, and therefore be unlikely to undergo a benign biopsy during an entire lifetime of annual screening. These risks are considerably lower than most women have expressed willingness to

accept. For example, in an attitudinal study of 479 US women, Schwartz et al³⁰ found that "women were highly tolerant of false positives: 63% thought that 500 or more false positives per life saved was reasonable and 37% would tolerate 10,000 or more."³⁰ On a related note, according to a study by Tosteson et al,³¹ "false-positive mammograms were associated with increased short-term anxiety but not long-term anxiety, and there was no measurable health utility decrement." That study also found that false-positive mammograms actually increased a woman's intention to undergo future screening and that most women would not drive any extra distance for screening with a lower likelihood of false-positives. Additionally, Table 3 shows that for annual screening starting at age 40, CISNET models estimated that 1 life-year would be saved for each benign biopsy experienced. One does not need an attitudinal survey to conclude that almost all women would be willing to undergo a benign biopsy to extend their life by 1 year.

The second screening strategy, in which women screen annually at ages 45 to 54 years and transition to biennial screening at age 55 years, is a hybrid of the first and third recommendations with respect to frequency and starting age. Of note, the current American College of Radiology/Society of Breast Imaging (first) recommendation is the former American Cancer Society guideline, with the exception of a shorter estimated longevity as a stopping age. Although one might suggest that this new (second) hybrid recommendation has outcomes very similar to those of the first recommendation, but with risks much closer to those of the third recommendation, our analysis based on 2009 CISNET demonstrates otherwise. Specifically, the benefits of mortality reduction and LYG for the (second) hybrid recommendation are approximately halfway between those of the first and third recommendations (Tables 2 and 3). Similarly, the estimated risks of benign recalls and benign biopsies for the (second) hybrid recommendation are approximately halfway between those of the first and third recommendations (Table 3). Although the second strategy models the ACS "strong" recommendation of annual screening at ages 45 to 54 years and biennial screening at ages 55 to 79 years, an ACS "qualified" recommendation states that "women should have the opportunity to begin annual screening between the ages of 40 and 44 years."¹ Based on 2009 CISNET, starting annual screening at age 40 years instead of age 45 years would increase mean mortality reduction from 30.8% to 32.7%, mean LYG from 149 to 163 per 1,000 women screened, and mean lives saved in the single-year cohort born in 1960 from 22,829 to 24,063.

Another ACS “qualified” recommendation is that women 55 years and older should have the opportunity to continue screening annually. Annual screening from age 55 to 79 years instead of biennial screening would increase mean mortality reduction from 23.5% to 28.3%, increase mean LYG from 97 to 118 per 1000 women screened, and mean lives saved in the single-year cohort from 17,399 to 20,978. Annual screening from age 40 to 79 years would result in both benefits and risks much closer to those of the first recommendation. We modeled the strongly recommended ACS hybrid strategy because it is widely discussed both in the medical and lay press. The “qualified” ACS recommendation supports more frequent and earlier onset screening that closely matches the American College of Radiology, American College of Obstetricians and Gynecologists, National Comprehensive Cancer Center Network, and Society of Breast Imaging recommendations. It is important to note that the ACS recommendations include the possibility of starting annual screening at age 40 years and undergoing annual rather than biennial screening after age 54 years, and that many women will likely choose to go beyond their minimum recommendation.

Just as RCTs, US population-based trends, and international service screening studies have their limitations, computer models have their own limitations. Models are a way to try to predict what might happen, but their outcomes depend heavily on their assumptions. If assumptions are incorrect or uncertain, then the validity of the results is less certain. Two CISNET models make the assumption that invasive breast cancers may fail to progress¹¹; however, extremely few cases of nonprogressive invasive breast cancer have been reported in the literature. One of the 6 models did not include DCIS at all, which is known to be a nonobligate precursor to invasive cancer.¹¹ Additionally, BCSC data used by CISNET considered screening within 9 and 18 months of a previous screening examination as “annual,” whereas screening between 18 and 30 months of a previous screening examination was considered “biennial” screening; therefore, biennial encompasses 3 more months than annual,³² potentially biasing “biennial” screening to detect more cancers. Other limitations include the assumption that all women adhere to each stated screening and treatment, rather than the variable adherence occurring in the real world.

We did not model overdiagnosis because of the wide range of frequency estimates reported in the literature and low level of reliability given to those estimates.¹⁷ However, our extensive clinical experience with modern mammography indicates that screen-detected cancers (including

overdiagnosed cancers), if not removed and left untreated, remain visible and suspicious for malignancy at next screening examination, so that a strategy involving less screening simply delays overdiagnosis but does not reduce it. Therefore, the frequency of both overdiagnosis and overtreatment likely are unaffected by the age at which screening starts (40 versus 45 versus 50) or by screening frequency.

In their concluding summary, CISNET authors state that “Choices about optimal ages of initiation and cessation will ultimately depend on program goals.”¹¹ If the screening program goal is to perform as few mammograms as possible to achieve limited benefit and fewer risks, with number of mammograms as a surrogate for cost, then the optimal age of initiation may be 50 years with an optimal frequency of biennial screening ending at age 74 years. On the other hand, if the goal is to avert the most breast cancer deaths and gain the most life-years, CISNET modeling shows that the optimal age of initiation for screening mammography is 40 years, the optimal screening frequency is annual, and the optimal stopping age is when a woman’s life expectancy is less than 5 to 7 years. Individual women should continue to have the choice to reduce their risk of dying from breast cancer as much as possible, and as CISNET models show, annual mammography starting at age 40 years is the best way to do so.

FUNDING SUPPORT

No specific funding was disclosed.

CONFLICTS OF INTEREST DISCLOSURES

R. Edward Hendrick has consulted for GE Healthcare. Mark A. Helvie has received institutional support from GE Healthcare.

AUTHOR CONTRIBUTIONS

Elizabeth Kagan Arleo: Conceptualization, methodology, validation, formal analysis, investigation, writing (original draft), writing (review and editing), supervision, and project administration. **R. Edward Hendrick:** Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. **Mark A. Helvie:** Conceptualization, methodology, validation, formal analysis, investigation, writing (original draft), writing (review and editing), and supervision. **Edward A. Sickles:** Conceptualization, methodology, writing (review and editing), and supervision.

REFERENCES

- Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. *JAMA*. 2015;314:1599-1614.
- Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. *Lancet*. 2012;380:1778-1786.

3. Howlander Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016.
4. Broeders M, Moss S, Nyström L, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. *J Med Screen*. 2012;19(Suppl 1):14-25.
5. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. *J Natl Cancer Inst*. 2015;107:dju404.
6. Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic screening and breast cancer mortality: a case-control study and meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2012;21:1479-1488.
7. Shetty MKE. Breast cancer screening and diagnosis. New York, NY: Springer; 2015.
8. Smith RA, Duffy SW, Tabar L. Breast cancer screening: the evolving evidence. *Oncology (Williston Park)*. 2012;26:471-475.
9. Warren JL, ed. Using SEER-medicare data for cancer survivorship research. 2012 Biennial Survivorship Conference. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2012.
10. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. *Ann Intern Med*. 2009;151:738-747.
11. Mandelblatt JS CK, de Koning H, Miglioretti DL, Schechter CS, Stout N. Model report: collaborative modeling of U.S. breast cancer screening strategies. AHRQ Publication No. 14-05201 EF-4. Rockville, MD: U.S. Preventive Services Task Force; 2015.
12. Mandelblatt JS, Stout NK, Schechter CB, et al. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. *Ann Intern Med*. 2016;164:215-225.
13. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009;151:716-726.
14. Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2016;164:279-296.
15. National Institutes of Health, National Cancer Institute Cancer, Intervention and Surveillance Modeling Network (CISNET). Breast cancer modeling. <https://cisnet.cancer.gov/breast/>. Accessed November 8, 2016.
16. U.S. Census Bureau. Census 2000 gateway. <http://www.census.gov/main/www/cen2000.html>. Accessed: November 8, 2016.
17. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2009;151:727-737.
18. Centers for Disease Control and Prevention. National vital statistics report. http://www.cdc.gov/nchs/data/nvsr/nvsr63/nvsr63_07.pdf. Accessed November 8, 2016.
19. US Food and Drug Administration. MQSA national statistics. <http://www.fda.gov/radiation-emittingproducts/mammographyqualitystandard-sactandprogram/facilityscorecard/ucm113858>. Accessed: November 8, 2016.
20. van Ravesteyn NT, Stout NK, Schechter CB, et al. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. *J Natl Cancer Inst*. 2015;107:djv103.
21. American College of Radiology. BI-RADS—follow-up and outcome monitoring: the basic clinically relevant audit. <http://www.acr.org/Quality-Safety/Resources/BIRADS/Monitoring>. Accessed November 8, 2016.
22. van Schoor G, Moss SM, Otten JD, et al. Increasingly strong reduction in breast cancer mortality due to screening. *Br J Cancer*. 2011;104:910-914.
23. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. *Cancer*. 2011;117:714-722.
24. Otto SJ, Fracheboud J, Verbeek AL, et al. Mammography screening and risk of breast cancer death: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev*. 2012;21:66-73.
25. Hofvind S, Ursin G, Tretli S, Sebuodegard S, Moller B. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. *Cancer*. 2013;119:3106-3112.
26. Paap E, Holland R, den Heeten GJ, et al. A remarkable reduction of breast cancer deaths in screened versus unscreened women: a case-referent study. *Cancer Causes Control*. 2010;21:1569-73.
27. Sigurdsson K, Olafsdottir EJ. Population-based service mammography screening: the Icelandic experience. *Breast Cancer (Dove Med Press)*. 2013;5:17-25.
28. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. *Lancet*. 2003;361:1405-1410.
29. Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. *J Natl Cancer Inst*. 2014;106:dju289.
30. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. *BMJ*. 2000;320:1635-1640.
31. Tosteson AN, Fryback DG, Hammond CS, et al. Consequences of false-positive screening mammograms. *JAMA Internal Medicine*. 2014;174:954-961.
32. Miglioretti DL, Zhu W, Kerlikowske K, et al. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. *JAMA Oncology*. 2015;1:1069-1077.